Skip to main content

Table 1 Patient's characteristics

From: Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission

Number of patients

91

Median age, years (range)

45 (16-75)

Male

44 (48.4)

Female

47 (51.6)

Prior therapy with interferon-α

29

Cytogenetic abnormalities in Ph-negative cells, no. (%)

5 (5.5%)

Time from initiation of imatinib to CCyR (months)

Median (range)

7

(6-50)

Time from initiation of imatinib to MMR (months)

Median (range)

18

(9-65)

Time from initiation of imatinib to CMR (months)

Median (range)

33

(5-78)

Time from achievement of CCyR to last evaluation (months)

Median (range)

57

(24-95)

Time from achievement of MMR to last evaluation (months)

Median (range)

36

(19-46)

Time from achievement of CMR to last evaluation (months)

Median (range)

22

(6-49)